Non small cell lung cancer medical therapy: Difference between revisions
No edit summary |
|||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Chemotherapy is indicated for non-small cell lung cancer stage (IB, II, and III) as adjuvant therapy. The predominant therapy for non-small cell lung cancer is surgical resection. Chemotherapy and chemoradiation may be required upon histological subtype of non-small cell lung cancer, location, size, and lymph node involvement. | Chemotherapy is indicated for non-small cell lung cancer stage (IB, II, and III) as adjuvant therapy. The predominant therapy for non-small cell lung cancer is surgical resection. Chemotherapy and chemoradiation may be required upon histological subtype of non-small cell lung cancer, location, size, and lymph node involvement. | ||
==Medical Therapy== | ==Medical Therapy== | ||
Line 16: | Line 14: | ||
:*ALK mutation (crizotinib) | :*ALK mutation (crizotinib) | ||
:*ROS1 mutation (crizotinib) | :*ROS1 mutation (crizotinib) | ||
*Chemotherapy is indicated for stage IB, II, and III non-small cell lung cancer | *Chemotherapy is indicated as adjuvant for stage IB, II, and III non-small cell lung cancer | ||
*Platinum-based chemotherapy (cisplatin, carboplatin, etoposide, irinotecan) are the mainstay of treatment for non-small cell lung cancer | *Platinum-based chemotherapy (cisplatin, carboplatin, etoposide, irinotecan) are the mainstay of treatment for non-small cell lung cancer | ||
*Platinum-based chemotherapy consists of four to six cycles | *Platinum-based chemotherapy consists of four to six cycles | ||
*In patients with non-squamous histology, platinum-based chemotherapy may be supplemented by bevacizumab | *In patients with non-squamous histology, platinum-based chemotherapy may be supplemented by bevacizumab. | ||
*Other chemotherapy regimens, such as: cyclophosphamide, doxorubicin (adriamycin), and vincristine may be an alternative for non-small cell lung cancer patients who are unable to tolerate a platinum-based chemotherapy | *Other chemotherapy regimens, such as: cyclophosphamide, doxorubicin (adriamycin), and vincristine may be an alternative for non-small cell lung cancer patients who are unable to tolerate a platinum-based chemotherapy | ||
*For non-small cell lung cancer patients with good treatment response and with stable disease after initial chemotherapy, maintenance therapy may prolong survival | |||
==Complications== | ==Complications== |
Revision as of 19:40, 1 March 2016
Non Small Cell Lung Cancer Microchapters |
Differentiating Non Small Cell Lung Cancer from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Non small cell lung cancer medical therapy On the Web |
American Roentgen Ray Society Images of Non small cell lung cancer medical therapy |
Directions to Hospitals Treating Non small cell carcinoma of the lung |
Risk calculators and risk factors for Non small cell lung cancer medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alonso Alvarado, M.D. [2] Maria Fernanda Villarreal, M.D. [3]
Overview
Chemotherapy is indicated for non-small cell lung cancer stage (IB, II, and III) as adjuvant therapy. The predominant therapy for non-small cell lung cancer is surgical resection. Chemotherapy and chemoradiation may be required upon histological subtype of non-small cell lung cancer, location, size, and lymph node involvement.
Medical Therapy
- Initial medical therapy for patients with non-small cell lung cancer will depend on tumor histology and molecular testing (presence of genetic mutations)
- If the tumor demonstrates absence of genetic mutation or is a squamous-cell tumor, the treatment of choice will be platinum-based chemotherapy
- If the tumor is a non-squamous cell tumor and positive for molecular testing, the treatment of choice will be with a specific-inhibitor, such as:
- EGFR mutation (erlotinib, gefitinib, afatinib)
- ALK mutation (crizotinib)
- ROS1 mutation (crizotinib)
- Chemotherapy is indicated as adjuvant for stage IB, II, and III non-small cell lung cancer
- Platinum-based chemotherapy (cisplatin, carboplatin, etoposide, irinotecan) are the mainstay of treatment for non-small cell lung cancer
- Platinum-based chemotherapy consists of four to six cycles
- In patients with non-squamous histology, platinum-based chemotherapy may be supplemented by bevacizumab.
- Other chemotherapy regimens, such as: cyclophosphamide, doxorubicin (adriamycin), and vincristine may be an alternative for non-small cell lung cancer patients who are unable to tolerate a platinum-based chemotherapy
- For non-small cell lung cancer patients with good treatment response and with stable disease after initial chemotherapy, maintenance therapy may prolong survival
Complications
- Medical therapy complications for non-small cell lung cancer will depend on the chemotherapeutic agent. Common chemotherapy complications, include:
- Platinum-based chemotherapy
- The main dose-limiting side effect of cancer treatment with platinum compounds, include:
- Other chemotherapy complications, include:
- Extravasation